Dr Sarah Sammons
@drsarahsam
Breast Medical Oncologist and Senior Physician @dfci_breastonc. Clinical Trial Leader. Mama, wife. Tweets= own opinion
Gene expression profiling in breast cancer brain mets Among matched pairs, 42% lost ER, 55% lost PR, 45% gained HER2 & 42% acquired a basal-like phenotype. BM showed ↓luminal markers & ↑immune genes, revealing molecular divergence from the primaries esmoopen.com/article/S2059-…
Leptomeningeal metastases remain one of the toughest challenges in oncology—sometimes presenting with no disease elsewhere. Early results from TUXEDO-3 with HER3-DXd offer hope. Patritumab deruxtecan (HER3-DXd) demonstrated encouraging activity in patients with LM from solid…
Established Investigators need to rank in the 4th percentile, whereas Early Investigators need to be in the 10th percentile. This means that among 80 reviews in a study section, only 3 will be below the 4th percentile. cancer.gov/grants-trainin…
🗨️ “It’s the best single agent treatment that we ever developed for metastatic #breastcancer.” @PTarantinoMD of @DanaFarber @Harvard on the real-world efficacy of trastuzumab deruxtecan, published in @ESMO_Open. @AstraZeneca @DaiichiSankyoUS bit.ly/4f2XQL3
Tangible goal to implement for everyone including cancer patients. 5000 steps a day looks quite good for all cause mortality.
Some plateauing for associated risk reduction (odds ratio) many outcomes seen at 7,000 steps
Check out this podcast where @DanaFarber's Sara Tolaney, MD, MPH discusses how the results from the DESTINY-Breast09 study are redefining first-line treatment in HER2-positive #MetastaticBreastCancer. She explores whether #TDXd plus #pertuzumab should replace the long-standing…
New in @CCR_AACR: Neoadj. CT+IO improves pCR, EFS & OS in TNBC, but among those who relapse, most do so early (<24m)—especially in pts with residual disease (see below). Urgent need for trials in this high-risk group: ICI+ADC? ICI+VEGF? Bispecifics? 🔗 doi.org/10.1158/1078-0…
There is an urgent need for a new age algorithm that takes huge existing data sets and calculates 3,5,10 year benefits to Chemotherapy, endocrine therapy, CDK4/6i and bisphosphonates in adjuvant HR+,HER2- Breast Cancer. Predict NHS but new and better. I’m sure AI could help.
I would agree! Early detection and improved therapies including immunotherapy have made early stage TNBC curable for most. Still room to improve detection, treatments, and side effects of treatment!
TNBC survival rates are rising. Thanks to early detection, treatment advances & the power of community, 5-year survival for early-stage TNBC has grown from under 77% to nearly 85%. Progress is real—& we’re not done yet. Source: tinyurl.com/54vcaz7u #TNBC #SurvivalRate
DYK 70% of Medicaid recipients already have a full or part time job? People who are unemployed or underemployed cite lack of housing and lack of childcare as major reasons they aren’t working. As states contemplate work requirements I hope the also contemplate work barriers…
Navigating life insurance after a breast cancer diagnosis can feel overwhelming, but you’re not alone, and you may have options. Our new resource breaks down what to expect when exploring life insurance options before, during, and after treatment: bit.ly/3IzLGxb…
Dr. @NarjustFlorezMD on the stage at #ALKSummit2025 discussing survivorship, including self care, communication, stigma, complementary medicine, weight management, and even how to manage a snoring spouse
Had the chance to chat about advance care planning - important for everyone to consider, not just those who are ill!
There's more to advance care planning for end of life than just filling out legal forms. In this Cancerwise podcast, our experts break down the important conversations patients and caregivers should also consider having throughout the process: spr.ly/6016fBFJG #EndCancer
I’m happy to share our latest work on tumour necrosis! During my time in the @megeblad lab, we found that tumour necrosis is not a passive phenomenon secondary to tumour growth, but an active phenomenon driven by neutrophils and NETs! Thread below: (1/13) nature.com/articles/s4158…
Dr. Erica Mayer (@elmayermd) started off Session VI on #ERpositive breast cancer with a comprehensive review of new treatment approaches in early ER+ #BreastCancer. She discussed adjuvant #CDK 4/6 inhibitors, neoadjuvant IO for HR+ disease, and oral #SERDs.…
Dr. Jennifer Ligibel closed out Day 1 of the #HarvardBreastCancerCourse with a special lecture on lifestyle, diet and exercise in #BreastCancer patients, touching on hot topics such as the #ChallengeTrial, #GLP1s and #weightloss.
Dr. Adrienne Waks (@adawaksmd) opened Session III on HER2+ #BreastCancer with an informative talk on new approaches in early stage #HER2positive breast cancer, reviewing treatment options for adjuvant and neoadjuvant therapy for stage II-III disease at the…
@drsarahsam from @DFCI_BreastOnc never fails to spark the most critical questions. How can we best integrate the DB09 results into clinical practice?
Expected pathological complete response rates in early stage II/III HER2+ breast cancer. #bcsm @DFCI_BreastOnc
